New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
07:53 EDTPRGO, MYL, VRX, ENDPPullback has created attractive pharma opportunities, says JPMorgan
JPMorgan believes nothing has fundamentally changed to warrant the recent pullback in the specialty pharmaceutical space and views the pullback as an attractive buying opportunity. JPMorgan named Endo Health (ENDP), Mylan (MYL), Perrigo (PRGO), and Valeant (VRX) as stocks on which it maintains Overweight ratings, citing their favorable positions given the wave of consolidation ongoing in the industry.
News For ENDP;MYL;PRGO;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
10:41 EDTMYLHigh option volume stocks
Subscribe for More Information
December 17, 2014
13:32 EDTPRGOPerrigo jumps after analyst discusses potential takeover by Teva
Subscribe for More Information
10:53 EDTVRXAckman says 'will take hard look' at Valeant shares after restrictions end
Subscribe for More Information
09:26 EDTPRGOPerrigo would be good acquisition for Teva, says RBC Capital
RBC Capital views Perrigo (PRGO) as an attractive acquisition target and says in a note to investors that it thinks a takeover could be a good strategic fit with solid accretion for Teva (TEVA). Teva has interest in over-the-counter products and its growth rate would be boosted by the merger, RBC believes. The firm assumes a $200 per share value for Perrigo in its acquisition assumptions. Shares of the over-the-counter and generic pharmaceuticals company closed yesterday at $153.77.
December 16, 2014
09:52 EDTMYLFDA ruling on generic Celebrex reversed by appeals court
Subscribe for More Information
08:58 EDTENDPEndo a top pick for 2015, says Sterne Agee
Subscribe for More Information
December 11, 2014
17:04 EDTENDPEndo registration statement relating to Auxilium declared effective by SEC
Subscribe for More Information
07:32 EDTMYLMylan launches generic version of Hikma Maple's Robaxin injection
Subscribe for More Information
07:06 EDTMYLMylan launches generic version of Orapred ODT
Mylan announced the U.S. launch of its Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg. This product is the first generic version of Shionogi's Orapred ODT. Mylan received final approval from the FDA for its Abbreviated New Drug Application for Prednisolone Sodium Phosphate Orally Disintegrating Tablets, 10 mg, 15 mg, and 30 mg, and was awarded 180 days of generic drug marketing exclusivity. This product is indicated as an anti-inflammatory or immunosuppressive agent for certain conditions; and also for the treatment of certain endocrine conditions, and for palliation of certain neoplastic conditions. Prednisolone Sodium Phosphate Orally Disintegrating Tablets had U.S. sales of approximately $19.9M for the 12 months ending September 30.
December 10, 2014
07:38 EDTMYLMylan launches generic version of Pfizer's Celebrex capsules
Mylan (MYL) announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's (PFE) Celebrex Capsules, indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults. Celecoxib Capsules had U.S. sales of approximately $2.5B for the 12 months ending September 30, 2014.
December 9, 2014
09:31 EDTVRXZoetis drops after report of Valeant abandoning growth by acquisitions strategy
Subscribe for More Information
07:08 EDTENDPEndo completes acquisition of rights to Natesto from Trimel BioPharma
Endo International announced the completion of the acquisition of rights to Natesto, a testosterone nasal gel, the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma, a wholly-owned subsidiary of Trimel Pharmaceuticals for $25M including additional payments upon the achievement of certain regulatory and sales milestones. Endo will collaborate with Trimel on all regulatory and clinical development activities regarding Natesto. Endo intends to launch the product, through its Endo Pharmaceuticals subsidiary, in the Q1 of 2015.
06:39 EDTVRXValeant to abandon growth by acquisitions strategy, Reuters says
Subscribe for More Information
December 8, 2014
11:30 EDTMYLLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
09:32 EDTENDPSyneron Medical signs agreement with AMS to supply holmium laser for urology
Subscribe for More Information
December 5, 2014
10:05 EDTMYLBristol-Myers jumps 2% amid talk of potential Pfizer bid
Shares of Bristol-Myers (BMY) are up in early trading amid chatter of a potential takeover bid from Pfizer (PFE). The stock is up $1.26 to $60.15. Bristol's market capitalization stands around $99B, less than twice that of Pfizer's $200B. A Jefferies analyst last week called Mylan (MYL) the most likely takeover target for Pfizer. Pfizer is "highly motivated" to buy a foreign company using its overseas cash and Mylan looks like the most likely target, Jefferies analyst Jeffrey Holford wrote.
December 4, 2014
10:03 EDTMYLMylan receives tentative FDA approval for abacavir/lamivudine NDAs
Mylan announced that its subsidiary Mylan Laboratories has received tentative approval from the FDA for its New Drug Applications for two dosages of abacavir/lamivudine tablets for oral suspension for the treatment of HIV-1 infection in pediatric patients. This is the first version of abacavir/lamivudine with scoring to allow for dose adjustment and is also flavored, Mylan said. The FDA's tentative approval through the President's Emergency Plan for AIDS Relief program means the formulations meet all of the agency's quality, safety and efficacy standards, it stated. The tentative approval follows a 2012 agreement between Mylan, Clinton Health Access Initiative and ViiV Healthcare to transfer the necessary technology and resources to facilitate regulatory authority submission, production and distribution of the new formulation to a total of 115 resource limited countries including all low-middle income, least developed countries and sub-Saharan Africa. Mylan's products are expected to be eligible for purchase in early 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use